Answers are grounded in this paper and cite their sources.
Infection with the Zika virus (ZIKV) poses a threat to human health. An improved understanding of the host Toll-like receptor response, disease onset, and viral clearance in vivo and in vitro may lead to the development of therapeutic or prophylactic interventions against viral infections. Currently, no clinically approved ZIKV vaccine is available, highlighting the need for its development. In this study, we discuss the progress in the Zika vaccine, including advances in the use of Toll-like receptor agonists as vaccine adjuvants to enhance vaccine efficacy.
No takes yet. Share an insight, caveat, or question.
Kayesh et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: